CD molecules (ligands)

Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3 -positive T cells and CLDN18.2 -expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma.In VitroGresonitamab

Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3 -positive T cells and CLDN18.2 -expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma.In VitroGresonitamab

Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3 -positive T cells and CLDN18.2 -expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma.In VitroGresonitamab

ICAM-1

ICAM-1

ICAM-2

ICAM-2

ICOS ligand

ICOS ligand

LIGHT

LIGHT

Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling.Form:Liquid